Alamar selects Abcam as a key provider of antibody content for its propriety NULISA technology platform FREMONT, Calif. and CAMBRIDGE, England, Jan. 4, 2022 /PRNewswire/ -- Alamar Biosciences (Alamar), a platform company focused on transforming the field of proteomics to enable the early detection of cancer and other diseases, and Abcam (AIM: ABC) (NASDAQ: ABCM), a global innovator in...